Source: PyroGenesis Canada Inc.
  • PyroGenesis (PYR) has received a $2.4 million payment from a major international iron ore producer
  • The payment was triggered by PyroGenesis’ delivery of four 1-MW plasma torch systems as a potential replacement for the client’s fossil-fuel burners
  • Torch installation and trials are slated to be finalized by Q2 2023
  • PyroGenesis offers advanced plasma processes and sustainable solutions to reduce greenhouse gases
  • PyroGenesis (PYR) opened with a loss of 1.42 per cent, trading at $1.38 per share

PyroGenesis (PYR) has received a $2.4 million payment from a major international iron ore producer.

The payment was triggered by PyroGenesis’ delivery of four 1-MW plasma torch systems for use in the client’s iron ore pelletization furnaces – a key upstream part of the steelmaking process.

The torches use renewable electricity, allowing the client to reduce its greenhouse gas emissions compared to conventional fossil-fuel burners.

Pelletization significantly reduces the cost of transporting iron ore, which is an essential feedstock for blast furnaces.

Torch installation and trials are slated to be finalized by Q2 2023.

PyroGenesis offers advanced plasma processes and sustainable solutions to reduce greenhouse gases.

PyroGenesis (PYR) opened with a loss of 1.42 per cent, trading at $1.38 per share.


More From The Market Online

Unsung profits: Three money-making penny stocks trading for cheap

To make money in stocks, you need to develop a strong sense for the irrational, a quality often found among cheaply priced penny stocks.

This small-cap gold stock keeps notching high-grade gold in Nevada 

Viva Gold (TSXV:VAU) continues to capitalize on the market thanks to its 100-per-cent-owned Tonopah project in west-central Nevada. 
stock market down

@ the Bell: TSX hits near-month high

The TSX rose near highs not seen in a month, but a split between indices capped gains as mining and energy were the only…

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.